Cardiac phosphodiesterase 5 (cGMP-specific) modulates β-adrenergic signaling in vivo and is down-regulated in heart failure

Hideaki Senzaki, Carolyn J. Smith, George J. Juang, Takayoshi Isoda, Sharon P. Mayer, Andreas Ohler, Nazareno Paolocci, Gordon F. Tomaselli, Joshua Hare, David A. Kass

Research output: Contribution to journalArticle

183 Citations (Scopus)

Abstract

Recent studies implicate increased cGMP synthesis as a postreceptor contributor to reduced cardiac sympathetic responsiveness. Here we provide the first evidence that modulation of this interaction by cGMP-specific phosphodiesterase PDE5A is also diminished in failing hearts, providing a novel mechanism for blunted β-adrenergic signaling in this disorder. In normal conscious dogs chronically instrumented for left ventricular pressure-dimension analysis, PDE5A inhibition by EMD82639 had modest basal effects but markedly blunted dobutamine-enhanced systolic and diastolic function. In failing hearts (tachypacing model), however, EMD82639 had negligible effects on either basal or dobutamine-stimulated function. Whole myocardium from failing hearts had 50% lower PDE5A protein expression and 30% less total and EMD92639-inhibitable cGMP-PDE activity. Although corresponding myocyte protein and enzyme activity was similar among groups, the proportion of EMD82639-inhibitable activity was significantly lower in failure cells. Immunohistochemistry confirmed PDE5A expression in both the vasculature and myocytes of normal and failing hearts, but there was loss of z-band localization in failing myocytes that suggested altered intracellular localization. Thus, PDE5A regulation of cGMP in the heart can potently modulate β-adrenergic stimulation, and alterations in enzyme localization and reduced synthesis may blunt this pathway in cardiac failure, contributing to dampening of the β-adrenergic response. - Senzaki, H., Smith, C. J., Juang, G. J., Isoda, T., Mayer, S. P., Ohler, A., Paolocci, N., Tomaselli, G. F., Hare, J. M., Kass, K. A. Cardiac phosphodiesterase 5 (cGMP-specific) modulates β-adrenergic signaling in vivo and is down-regulated in heart failure.

Original languageEnglish
Pages (from-to)1718-1726
Number of pages9
JournalFASEB Journal
Volume15
Issue number10
DOIs
StatePublished - Aug 20 2001
Externally publishedYes

Fingerprint

Type 5 Cyclic Nucleotide Phosphodiesterases
heart failure
Adrenergic Agents
Heart Failure
heart
myocytes
Muscle Cells
Dobutamine
Hares
synthesis
hares
Phosphoric Diester Hydrolases
Ventricular Pressure
Enzymes
myocardium
Enzyme activity
immunohistochemistry
Myocardium
Proteins
protein synthesis

Keywords

  • Coronary blood flow
  • PDE5
  • Protein expression
  • Tissue activity

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

Senzaki, H., Smith, C. J., Juang, G. J., Isoda, T., Mayer, S. P., Ohler, A., ... Kass, D. A. (2001). Cardiac phosphodiesterase 5 (cGMP-specific) modulates β-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB Journal, 15(10), 1718-1726. https://doi.org/10.1096/fj.00-0538com

Cardiac phosphodiesterase 5 (cGMP-specific) modulates β-adrenergic signaling in vivo and is down-regulated in heart failure. / Senzaki, Hideaki; Smith, Carolyn J.; Juang, George J.; Isoda, Takayoshi; Mayer, Sharon P.; Ohler, Andreas; Paolocci, Nazareno; Tomaselli, Gordon F.; Hare, Joshua; Kass, David A.

In: FASEB Journal, Vol. 15, No. 10, 20.08.2001, p. 1718-1726.

Research output: Contribution to journalArticle

Senzaki, H, Smith, CJ, Juang, GJ, Isoda, T, Mayer, SP, Ohler, A, Paolocci, N, Tomaselli, GF, Hare, J & Kass, DA 2001, 'Cardiac phosphodiesterase 5 (cGMP-specific) modulates β-adrenergic signaling in vivo and is down-regulated in heart failure', FASEB Journal, vol. 15, no. 10, pp. 1718-1726. https://doi.org/10.1096/fj.00-0538com
Senzaki, Hideaki ; Smith, Carolyn J. ; Juang, George J. ; Isoda, Takayoshi ; Mayer, Sharon P. ; Ohler, Andreas ; Paolocci, Nazareno ; Tomaselli, Gordon F. ; Hare, Joshua ; Kass, David A. / Cardiac phosphodiesterase 5 (cGMP-specific) modulates β-adrenergic signaling in vivo and is down-regulated in heart failure. In: FASEB Journal. 2001 ; Vol. 15, No. 10. pp. 1718-1726.
@article{fb480ebba7d24b5688bbd18c5a967448,
title = "Cardiac phosphodiesterase 5 (cGMP-specific) modulates β-adrenergic signaling in vivo and is down-regulated in heart failure",
abstract = "Recent studies implicate increased cGMP synthesis as a postreceptor contributor to reduced cardiac sympathetic responsiveness. Here we provide the first evidence that modulation of this interaction by cGMP-specific phosphodiesterase PDE5A is also diminished in failing hearts, providing a novel mechanism for blunted β-adrenergic signaling in this disorder. In normal conscious dogs chronically instrumented for left ventricular pressure-dimension analysis, PDE5A inhibition by EMD82639 had modest basal effects but markedly blunted dobutamine-enhanced systolic and diastolic function. In failing hearts (tachypacing model), however, EMD82639 had negligible effects on either basal or dobutamine-stimulated function. Whole myocardium from failing hearts had 50{\%} lower PDE5A protein expression and 30{\%} less total and EMD92639-inhibitable cGMP-PDE activity. Although corresponding myocyte protein and enzyme activity was similar among groups, the proportion of EMD82639-inhibitable activity was significantly lower in failure cells. Immunohistochemistry confirmed PDE5A expression in both the vasculature and myocytes of normal and failing hearts, but there was loss of z-band localization in failing myocytes that suggested altered intracellular localization. Thus, PDE5A regulation of cGMP in the heart can potently modulate β-adrenergic stimulation, and alterations in enzyme localization and reduced synthesis may blunt this pathway in cardiac failure, contributing to dampening of the β-adrenergic response. - Senzaki, H., Smith, C. J., Juang, G. J., Isoda, T., Mayer, S. P., Ohler, A., Paolocci, N., Tomaselli, G. F., Hare, J. M., Kass, K. A. Cardiac phosphodiesterase 5 (cGMP-specific) modulates β-adrenergic signaling in vivo and is down-regulated in heart failure.",
keywords = "Coronary blood flow, PDE5, Protein expression, Tissue activity",
author = "Hideaki Senzaki and Smith, {Carolyn J.} and Juang, {George J.} and Takayoshi Isoda and Mayer, {Sharon P.} and Andreas Ohler and Nazareno Paolocci and Tomaselli, {Gordon F.} and Joshua Hare and Kass, {David A.}",
year = "2001",
month = "8",
day = "20",
doi = "10.1096/fj.00-0538com",
language = "English",
volume = "15",
pages = "1718--1726",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "10",

}

TY - JOUR

T1 - Cardiac phosphodiesterase 5 (cGMP-specific) modulates β-adrenergic signaling in vivo and is down-regulated in heart failure

AU - Senzaki, Hideaki

AU - Smith, Carolyn J.

AU - Juang, George J.

AU - Isoda, Takayoshi

AU - Mayer, Sharon P.

AU - Ohler, Andreas

AU - Paolocci, Nazareno

AU - Tomaselli, Gordon F.

AU - Hare, Joshua

AU - Kass, David A.

PY - 2001/8/20

Y1 - 2001/8/20

N2 - Recent studies implicate increased cGMP synthesis as a postreceptor contributor to reduced cardiac sympathetic responsiveness. Here we provide the first evidence that modulation of this interaction by cGMP-specific phosphodiesterase PDE5A is also diminished in failing hearts, providing a novel mechanism for blunted β-adrenergic signaling in this disorder. In normal conscious dogs chronically instrumented for left ventricular pressure-dimension analysis, PDE5A inhibition by EMD82639 had modest basal effects but markedly blunted dobutamine-enhanced systolic and diastolic function. In failing hearts (tachypacing model), however, EMD82639 had negligible effects on either basal or dobutamine-stimulated function. Whole myocardium from failing hearts had 50% lower PDE5A protein expression and 30% less total and EMD92639-inhibitable cGMP-PDE activity. Although corresponding myocyte protein and enzyme activity was similar among groups, the proportion of EMD82639-inhibitable activity was significantly lower in failure cells. Immunohistochemistry confirmed PDE5A expression in both the vasculature and myocytes of normal and failing hearts, but there was loss of z-band localization in failing myocytes that suggested altered intracellular localization. Thus, PDE5A regulation of cGMP in the heart can potently modulate β-adrenergic stimulation, and alterations in enzyme localization and reduced synthesis may blunt this pathway in cardiac failure, contributing to dampening of the β-adrenergic response. - Senzaki, H., Smith, C. J., Juang, G. J., Isoda, T., Mayer, S. P., Ohler, A., Paolocci, N., Tomaselli, G. F., Hare, J. M., Kass, K. A. Cardiac phosphodiesterase 5 (cGMP-specific) modulates β-adrenergic signaling in vivo and is down-regulated in heart failure.

AB - Recent studies implicate increased cGMP synthesis as a postreceptor contributor to reduced cardiac sympathetic responsiveness. Here we provide the first evidence that modulation of this interaction by cGMP-specific phosphodiesterase PDE5A is also diminished in failing hearts, providing a novel mechanism for blunted β-adrenergic signaling in this disorder. In normal conscious dogs chronically instrumented for left ventricular pressure-dimension analysis, PDE5A inhibition by EMD82639 had modest basal effects but markedly blunted dobutamine-enhanced systolic and diastolic function. In failing hearts (tachypacing model), however, EMD82639 had negligible effects on either basal or dobutamine-stimulated function. Whole myocardium from failing hearts had 50% lower PDE5A protein expression and 30% less total and EMD92639-inhibitable cGMP-PDE activity. Although corresponding myocyte protein and enzyme activity was similar among groups, the proportion of EMD82639-inhibitable activity was significantly lower in failure cells. Immunohistochemistry confirmed PDE5A expression in both the vasculature and myocytes of normal and failing hearts, but there was loss of z-band localization in failing myocytes that suggested altered intracellular localization. Thus, PDE5A regulation of cGMP in the heart can potently modulate β-adrenergic stimulation, and alterations in enzyme localization and reduced synthesis may blunt this pathway in cardiac failure, contributing to dampening of the β-adrenergic response. - Senzaki, H., Smith, C. J., Juang, G. J., Isoda, T., Mayer, S. P., Ohler, A., Paolocci, N., Tomaselli, G. F., Hare, J. M., Kass, K. A. Cardiac phosphodiesterase 5 (cGMP-specific) modulates β-adrenergic signaling in vivo and is down-regulated in heart failure.

KW - Coronary blood flow

KW - PDE5

KW - Protein expression

KW - Tissue activity

UR - http://www.scopus.com/inward/record.url?scp=17844381569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17844381569&partnerID=8YFLogxK

U2 - 10.1096/fj.00-0538com

DO - 10.1096/fj.00-0538com

M3 - Article

C2 - 11481219

AN - SCOPUS:17844381569

VL - 15

SP - 1718

EP - 1726

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 10

ER -